Cargando…

The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome

BACKGROUND: The role of recombinant activated protein C (aPC) during sepsis is still controversial. It showed anti-inflammatory effect and improved the microvascular perfusion in experimental models of septic shock. The present study was aimed at testing the hypothesis that recombinant aPC therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Donati, Abele, Damiani, Elisa, Botticelli, Laura, Adrario, Erica, Lombrano, Maria Rita, Domizi, Roberta, Marini, Benedetto, Van Teeffelen, Jurgen WGE, Carletti, Paola, Girardis, Massimo, Pelaia, Paolo, Ince, Can
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848895/
https://www.ncbi.nlm.nih.gov/pubmed/24070065
http://dx.doi.org/10.1186/1471-2253-13-25
_version_ 1782293841635704832
author Donati, Abele
Damiani, Elisa
Botticelli, Laura
Adrario, Erica
Lombrano, Maria Rita
Domizi, Roberta
Marini, Benedetto
Van Teeffelen, Jurgen WGE
Carletti, Paola
Girardis, Massimo
Pelaia, Paolo
Ince, Can
author_facet Donati, Abele
Damiani, Elisa
Botticelli, Laura
Adrario, Erica
Lombrano, Maria Rita
Domizi, Roberta
Marini, Benedetto
Van Teeffelen, Jurgen WGE
Carletti, Paola
Girardis, Massimo
Pelaia, Paolo
Ince, Can
author_sort Donati, Abele
collection PubMed
description BACKGROUND: The role of recombinant activated protein C (aPC) during sepsis is still controversial. It showed anti-inflammatory effect and improved the microvascular perfusion in experimental models of septic shock. The present study was aimed at testing the hypothesis that recombinant aPC therapy improves the microcirculation during severe sepsis. METHODS: Prospective observational study on patients admitted in a 12-beds intensive care unit of a university hospital from July 2010 to December 2011, with severe sepsis and at least two sepsis-induced organ failures occurring within 48 hours from the onset of sepsis, who received an infusion of aPC (24 mcg/kg/h for 96 hours) (aPC group). Patients with contraindications to aPC administration were also monitored (no-aPC group). At baseline (before starting aPC infusion, T0), after 24 hours (T1a), 48 hours (T1b), 72 hours (T1c) and 6 hours after the end of aPC infusion (T2), general clinical and hemodynamic parameters were collected and the sublingual microcirculation was evaluated with sidestream dark-field imaging. Total vessel density (TVD), perfused vessel density (PVD), De Backer score, microvascular flow index (MFIs), the proportion of perfused vessels (PPV) and the flow heterogeneity index (HI) were calculated for small vessels. The perfused boundary region (PBR) was measured as an index of glycocalyx damage. Variables were compared between time points and groups using non parametric or parametric statistical tests, as appropriate. RESULTS: In the 13 aPC patients mean arterial pressure (MAP), base excess, lactate, PaO2/FiO2 and the Sequential Organ Failure Assessment (SOFA) score significantly improved over time, while CI and ITBVI did not change. MFIs, TVD, PVD, PPV significantly increased over time and the HI decreased (p < 0.05 in all cases), while the PBR did not change. No-aPC patients (n = 9) did not show any change in the microcirculation over time. A positive correlation was found between MFIs and MAP. TVD, PVD and De Backer score negatively correlated with norepinephrine dose, and the SOFA score negatively correlated with MFIs, TVD and PVD. CONCLUSIONS: aPC significantly improves the microcirculation in patients with severe sepsis/septic shock. TRIAL REGISTRATION: NCT01806428
format Online
Article
Text
id pubmed-3848895
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38488952013-12-04 The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome Donati, Abele Damiani, Elisa Botticelli, Laura Adrario, Erica Lombrano, Maria Rita Domizi, Roberta Marini, Benedetto Van Teeffelen, Jurgen WGE Carletti, Paola Girardis, Massimo Pelaia, Paolo Ince, Can BMC Anesthesiol Research Article BACKGROUND: The role of recombinant activated protein C (aPC) during sepsis is still controversial. It showed anti-inflammatory effect and improved the microvascular perfusion in experimental models of septic shock. The present study was aimed at testing the hypothesis that recombinant aPC therapy improves the microcirculation during severe sepsis. METHODS: Prospective observational study on patients admitted in a 12-beds intensive care unit of a university hospital from July 2010 to December 2011, with severe sepsis and at least two sepsis-induced organ failures occurring within 48 hours from the onset of sepsis, who received an infusion of aPC (24 mcg/kg/h for 96 hours) (aPC group). Patients with contraindications to aPC administration were also monitored (no-aPC group). At baseline (before starting aPC infusion, T0), after 24 hours (T1a), 48 hours (T1b), 72 hours (T1c) and 6 hours after the end of aPC infusion (T2), general clinical and hemodynamic parameters were collected and the sublingual microcirculation was evaluated with sidestream dark-field imaging. Total vessel density (TVD), perfused vessel density (PVD), De Backer score, microvascular flow index (MFIs), the proportion of perfused vessels (PPV) and the flow heterogeneity index (HI) were calculated for small vessels. The perfused boundary region (PBR) was measured as an index of glycocalyx damage. Variables were compared between time points and groups using non parametric or parametric statistical tests, as appropriate. RESULTS: In the 13 aPC patients mean arterial pressure (MAP), base excess, lactate, PaO2/FiO2 and the Sequential Organ Failure Assessment (SOFA) score significantly improved over time, while CI and ITBVI did not change. MFIs, TVD, PVD, PPV significantly increased over time and the HI decreased (p < 0.05 in all cases), while the PBR did not change. No-aPC patients (n = 9) did not show any change in the microcirculation over time. A positive correlation was found between MFIs and MAP. TVD, PVD and De Backer score negatively correlated with norepinephrine dose, and the SOFA score negatively correlated with MFIs, TVD and PVD. CONCLUSIONS: aPC significantly improves the microcirculation in patients with severe sepsis/septic shock. TRIAL REGISTRATION: NCT01806428 BioMed Central 2013-09-26 /pmc/articles/PMC3848895/ /pubmed/24070065 http://dx.doi.org/10.1186/1471-2253-13-25 Text en Copyright © 2013 Donati et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Donati, Abele
Damiani, Elisa
Botticelli, Laura
Adrario, Erica
Lombrano, Maria Rita
Domizi, Roberta
Marini, Benedetto
Van Teeffelen, Jurgen WGE
Carletti, Paola
Girardis, Massimo
Pelaia, Paolo
Ince, Can
The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome
title The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome
title_full The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome
title_fullStr The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome
title_full_unstemmed The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome
title_short The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome
title_sort apc treatment improves microcirculation in severe sepsis/septic shock syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848895/
https://www.ncbi.nlm.nih.gov/pubmed/24070065
http://dx.doi.org/10.1186/1471-2253-13-25
work_keys_str_mv AT donatiabele theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT damianielisa theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT botticellilaura theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT adrarioerica theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT lombranomariarita theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT domiziroberta theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT marinibenedetto theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT vanteeffelenjurgenwge theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT carlettipaola theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT girardismassimo theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT pelaiapaolo theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT incecan theapctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT donatiabele apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT damianielisa apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT botticellilaura apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT adrarioerica apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT lombranomariarita apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT domiziroberta apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT marinibenedetto apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT vanteeffelenjurgenwge apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT carlettipaola apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT girardismassimo apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT pelaiapaolo apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome
AT incecan apctreatmentimprovesmicrocirculationinseveresepsissepticshocksyndrome